journal
https://read.qxmd.com/read/23259067/cell-type-specific-effects-of-silibinin-on-vitamin-d-induced-differentiation-of-acute-myeloid-leukemia-cells-are-associated-with-differential-modulation-of-rxr%C3%AE-levels
#21
JOURNAL ARTICLE
Rina Wassermann, Victoria Novik, Michael Danilenko
Plant polyphenols have been shown to enhance the differentiation of acute myeloid leukemia (AML) cells induced by the hormonal form of vitamin D(3) (1α,25-dihydroxyvitamin D(3); 1,25D). However, how these agents modulate 1,25D effects in different subtypes of AML cells remains poorly understood. Here, we show that both carnosic acid (CA) and silibinin (SIL) synergistically enhancd 1,25D-induced differentiation of myeloblastic HL60 cells. However, in promonocytic U937 cells, only CA caused potentiation while SIL attenuated 1,25D effect...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23259066/is-there-a-role-for-htlv-1-specific-ctl-in-adult-t-cell-leukemia-lymphoma
#22
JOURNAL ARTICLE
Aileen G Rowan, Charles R M Bangham
ATLL is an aggressive malignancy of T cells that affects about 5% of individuals infected with HTLV-1. The precise mechanism of oncogenesis is not known, but there is evidence that two regulatory viral proteins, Tax and HBZ, are involved. A high set point proviral load is associated with development of ATLL or a chronic inflammatory condition, HAM/TSP. Several lines of evidence, including HLA class 1 association studies and in vitro killing assays, indicate that cytotoxic T lymphocytes are instrumental in determining this proviral load set point...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23259065/differentiation-and-cell-survival-of-myeloid-leukemia-cells
#23
JOURNAL ARTICLE
George P Studzinski, Geoffrey Brown, Michael Danilenko, Philip Hughes, Ewa Marcinkowska
No abstract text is available yet for this article.
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23259064/clinical-trials-and-treatment-of-atl
#24
JOURNAL ARTICLE
Kunihiro Tsukasaki, Kensei Tobinai
ATL is a distinct peripheral T-lymphocytic malignancy associated with human T-cell lymphotropic virus type I (HTLV-1). The diversity in clinical features and prognosis of patients with this disease has led to its subtype-classification into four categories, acute, lymphoma, chronic, and smoldering types, defined by organ involvement, and LDH and calcium values. In case of acute, lymphoma, or unfavorable chronic subtypes (aggressive ATL), intensive chemotherapy like the LSG15 regimen (VCAP-AMP-VECP) is usually recommended if outside of clinical trials, based on the results of a phase 3 trial...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23213554/cotranscriptional-chromatin-remodeling-by-small-rna-species-an-htlv-1-perspective
#25
JOURNAL ARTICLE
Nishat Aliya, Saifur Rahman, Zafar K Khan, Pooja Jain
Cell type specificity of human T cell leukemia virus 1 has been proposed as a possible reason for differential viral outcome in primary target cells versus secondary. Through chromatin remodeling, the HTLV-1 transactivator protein Tax interacts with cellular factors at the chromosomally integrated viral promoter to activate downstream genes and control viral transcription. RNA interference is the host innate defense mechanism mediated by short RNA species (siRNA or miRNA) that regulate gene expression. There exists a close collaborative functioning of cellular transcription factors with miRNA in order to regulate the expression of a number of eukaryotic genes including those involved in suppression of cell growth, induction of apoptosis, as well as repressing viral replication and propagation...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23213553/retinoid-differentiation-therapy-for-common-types-of-acute-myeloid-leukemia
#26
JOURNAL ARTICLE
Geoffrey Brown, Philip Hughes
Many cancers arise in a tissue stem cell, and cell differentiation is impaired resulting in an accumulation of immature cells. The introduction of all-trans retinoic acid (ATRA) in 1987 to treat acute promyelocytic leukemia (APL), a rare subtype of acute myeloid leukemia (AML), pioneered a new approach to obtain remission in malignancies by restoring the terminal maturation of leukemia cells resulting in these cells having a limited lifespan. Differentiation therapy also offers the prospect of a less aggressive treatment by virtue of attenuated growth of leukemia cells coupled to limited damage to normal cells...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23213552/clinical-trials-of-adult-t-cell-leukaemia-lymphoma-treatment
#27
JOURNAL ARTICLE
Ambroise Marçais, Felipe Suarez, David Sibon, Ali Bazarbachi, Olivier Hermine
Adult T-cell leukaemia/lymphoma (ATLL) is an aggressive malignancy of mature activated T cells caused by human T-cell lymphotropic virus type I (HTLV-1). Prognosis is severe because of intrinsic chemoresistance and severe immuosuppression. Four different subtypes are described with different outcomes, and treatment strategies vary according to the different clinical courses. Japanese trials show that combinations of chemotherapy can increase the response rates especially in the lymphoma subtype. However, patients have a high rate of relapse and the outcome remains extremely poor...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23213551/comparison-of-the-genetic-organization-expression-strategies-and-oncogenic-potential-of-htlv-1-and-htlv-2
#28
JOURNAL ARTICLE
Francesca Rende, Ilaria Cavallari, Maria Grazia Romanelli, Erica Diani, Umberto Bertazzoni, Vincenzo Ciminale
Human T cell leukemia virus types 1 and 2 (HTLV-1 and HTLV-2) are genetically related complex retroviruses that are capable of immortalizing human T-cells in vitro and establish life-long persistent infections in vivo. In spite of these apparent similarities, HTLV-1 and HTLV-2 exhibit a significantly different pathogenic potential. HTLV-1 is recognized as the causative agent of adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). In contrast, HTLV-2 has not been causally linked to human malignancy, although it may increase the risk of developing inflammatory neuropathies and infectious diseases...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23213550/mycophenolic-acid-overcomes-imatinib-and-nilotinib-resistance-of-chronic-myeloid-leukemia-cells-by-apoptosis-or-a-senescent-like-cell-cycle-arrest
#29
JOURNAL ARTICLE
Claire Drullion, Valérie Lagarde, Romain Gioia, Patrick Legembre, Muriel Priault, Bruno Cardinaud, Eric Lippert, François-Xavier Mahon, Jean-Max Pasquet
We used K562 cells sensitive or generated resistant to imatinib or nilotinib to investigate their response to mycophenolic acid (MPA). MPA induced DNA damage leading to cell death with a minor contribution of apoptosis, as revealed by annexin V labeling (up to 25%). In contrast, cell cycle arrest and positive staining for senescence-associated β-galactosidase activity were detected for a large cell population (80%). MPA-induced cell death was potentialized by the inhibition of autophagy and this is associated to the upregulation of apoptosis...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23213549/regulation-of-leukemic-cell-differentiation-through-the-vitamin-d-receptor-at-the-levels-of-intracellular-signal-transduction-gene-transcription-and-protein-trafficking-and-stability
#30
JOURNAL ARTICLE
Elżbieta Gocek, Hanna Baurska, Aleksandra Marchwicka, Ewa Marcinkowska
1α,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D) exerts its biological activities through vitamin D receptor (VDR), which is a member of the superfamily of steroid receptors, that act as ligand-dependent transcription factors. Ligated VDR in complex with retinoid X receptor (RXR) binds to regulatory regions of 1,25(OH)(2)D-target genes. 1,25(OH)(2)D is able to induce differentiation of leukemic blasts towards macrophage-like cells. Many different acute myeloid leukemia (AML) cell lines respond to 1,25(OH)(2)D by increasing CD14 cell surface receptor, some additionally upregulate CD11b and CD11c integrins...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23213548/influence-of-il10-g1082a-and-tnf%C3%AE-g308a-polymorphisms-on-the-survival-of-pediatric-patients-with-all
#31
JOURNAL ARTICLE
Dayse Maria Vasconcelos de Deus, Karina Araújo Lugo, Maria Tereza Cartaxo Muniz
Interleukin 10 (IL10) is a pleiotropic cytokine that stimulates various hematopoietic cells. The tumor necrosis factor alpha (TNFα) is a cytokine that may influence the transcriptional activity induced by glucocorticoids. This study examined the impact of TNFα (G308A) and IL10 (G1082A) polymorphisms at promoter regions in relation to the overall survival of 105 children (0 ≤ 18 years) with acute lymphoblastic leukemia (ALL) for a period of 126 months, treated according to the protocol GBTLI99. The G1082A and G308A polymorphisms were identified by allele-specific PCR and PCR-RFLP, respectively...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23213547/important-genes-in-the-pathogenesis-of-5q-syndrome-and-their-connection-with-ribosomal-stress-and-the-innate-immune-system-pathway
#32
JOURNAL ARTICLE
Ota Fuchs
Myelodysplastic syndrome (MDS) with interstitial deletion of a segment of the long arm of chromosome 5q [del(5q)] is characterized by bone marrow erythroid hyperplasia, atypical megakaryocytes, thrombocythemia, refractory anemia, and low risk of progression to acute myeloid leukemia (AML) compared with other types of MDS. The long arm of chromosome 5 contains two distinct commonly deleted regions (CDRs). The more distal CDR lies in 5q33.1 and contains 40 protein-coding genes and genes coding microRNAs (miR-143, miR-145)...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23198157/influence-of-methylenetetrahydrofolate-reductase-c677t-a1298c-and-g80a-polymorphisms-on-the-survival-of-pediatric-patients-with-acute-lymphoblastic-leukemia
#33
JOURNAL ARTICLE
Dayse Maria Vasconcelos de Deus, Elker Lene Santos de Lima, Rafaela Maria Seabra Silva, Edinalva Pereira Leite, Maria Tereza Cartaxo Muniz
The influence of genic polymorphisms involved in metabolism of chemotherapeutic agents as the methotrexate (MTX) has been studied mainly in acute lymphoblastic leukemia (ALL) of childhood. Advances in treatment may be attributed to identification of prognostic factors added to chemotherapy protocol. The aim of this study was to analyze the association of the C677T, A1298C, and G80A polymorphisms on MTHFR gene and on the overall survival of pediatric patients (n = 126) with lymphoblastic leukemia treated with MTX according to the Brazilian protocol in 187 months...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23198156/diffuse-large-b-cell-lymphoma-in-human-t-lymphotropic-virus-type-1-carriers
#34
JOURNAL ARTICLE
Brady E Beltran, Pilar Quiñones, Domingo Morales, Jose C Revilla, Jose C Alva, Jorge J Castillo
We describe the clinical and pathological characteristics of seven patients who were human T-lymphotropic virus type 1 (HTLV-1) carriers and had a pathological diagnosis of de novo diffuse large B-cell lymphoma. Interestingly, three of our cases showed positive expression of Epstein-Barr-virus, (EBV-) encoded RNA within the tumor cells indicating a possible interaction between these two viruses. Furthermore, our three EBV-positive cases presented with similar clinical characteristics such as early clinical stage and low-risk indices...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23198155/immunopathogenesis-of-human-t-cell-leukemia-virus-type-1-associated-myelopathy-tropical-spastic-paraparesis-recent-perspectives
#35
JOURNAL ARTICLE
Mineki Saito, Charles R M Bangham
Human T-cell leukemia virus type-1 (HTLV-1) is a replication-competent human retrovirus associated with two distinct types of disease only in a minority of infected individuals: the malignancy known as adult T-cell leukemia (ATL) and a chronic inflammatory central nervous system disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HAM/TSP is a chronic progressive myelopathy characterized by spastic paraparesis, sphincter dysfunction, and mild sensory disturbance in the lower extremities...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23198154/factor-v-leiden-and-prothrombin-20210a-mutations-among-turkish-pediatric-leukemia-patients
#36
JOURNAL ARTICLE
Dilara Fatma Akın, Kadir Sipahi, Tuğba Kayaalp, Yonca Eğin, Serpil Taşdelen, Emin Kürekçi, Ustün Ezer, Nejat Akar
This study was undertaken to determine the prevalence of the Factor V 1691 G-A and PT 20210 G-A mutations in Turkish children with leukemia. We genotyped 135 pediatric leukemia patients with for these mutations. Eleven (8%) of the 135 patients were heterozygous for the FV 1691 G-A mutation. Seven (5,1%) of the patients carried the PT 20210 G-A heterozygous mutation. Of the 135 patients, only three had thrombotic event, none of which had these two mutations, which is common in Turkish population. Our findings revealed a controversial compared to the previous reports, which needs further investigation...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23198153/molecular-and-cellular-mechanism-of-leukemogenesis-of-atl-emergent-evidence-of-a-significant-role-for-hbz-in-htlv-1-induced-pathogenesis
#37
JOURNAL ARTICLE
Yorifumi Satou, Masao Matsuoka
Adult T-cell leukemia (ATL) is a leukemia derived from mature CD4(+) T cells and induced by human T-cell leukemia virus type 1 (HTLV-1) infection. Previous studies have revealed many possible molecular and cellular mechanisms of HTLV-1-induced leukemogenesis, but it still remains unknown how HTLV-1 transforms peripheral CD4 T cells in infected individuals. Given the fact that only 2-5% of infected individuals develop ATL, HTLV-1 infection alone is not sufficient for the transformation of infected cells. Host genetic and epigenetic abnormalities and host immunological status should be considered in attempting to understand the mechanism of the oncogenesis of ATL...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23198152/identification-of-a-novel-p190-derived-breakpoint-peptide-suitable-for-peptide-vaccine-therapeutic-approach-in-ph-acute-lymphoblastic-leukemia-patients
#38
JOURNAL ARTICLE
Micaela Ippoliti, Marzia Defina, Antonella Gozzini, Claudia Baratè, Lara Aprile, Alice Pietrini, Alessandro Gozzetti, Donatella Raspadori, Francesco Lauria, Monica Bocchia
Ph+ acute lymphoblastic leukemia (Ph+ ALL) is a high-risk acute leukemia with poor prognosis, in which the specific t(9;22)(q34;q11) translocation results in a chimeric bcr-abl (e1a2 breakpoint) and in a 190 KD protein (p190) with constitutive tyrosine kinase activity. The advent of first- and second-generation tyrosine kinase inhibitors (TKIs) improved the short-term outcome of Ph+ ALL patients not eligible for allo-SCT; yet disease recurrence is almost inevitable. Peptides derived from p190-breakpoint area are leukemia-specific antigens that may mediate an antitumor response toward p190+ leukemia cells...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23198151/pathogenesis-of-metastatic-calcification-and-acute-pancreatitis-in-adult-t-cell-leukemia-under-hypercalcemic-state
#39
JOURNAL ARTICLE
Masachika Senba, Kioko Kawai, Naoki Mori
Human T-cell leukemia virus type-1 (HTLV-1) is the causative agent of adult T-cell leukemia (ATL). Hypercalcemia is common in patients with ATL. These patients rarely develop metastatic calcification and acute pancreatitis. The underlying pathogenesis of this condition is osteoclast hyperactivity with associated overproduction of parathyroid hormone-related protein, which results in hypercalcemia in association with bone demineralization. The discovery of the osteoclast differentiation factor receptor activator of nuclear factor-κB ligand (RANKL), its receptor RANK, and its decoy receptor osteoprotegerin (OPG), enhanced our understanding of the mechanisms of ATL-associated hypercalcemia...
2012: Leukemia Research and Treatment
https://read.qxmd.com/read/23198150/clinical-experience-using-vitamin-d-and-analogs-in-the-treatment-of-myelodysplasia-and-acute-myeloid-leukemia-a-review-of-the-literature
#40
JOURNAL ARTICLE
Jonathan S Harrison, Alexander Bershadskiy
Despite progress in understanding the biology of acute myeloid leukemia (AML), and despite advances in treatment, the majority of patients with AML die from the disease. The observation that Vitamin D can induce AML blast cells in vitro to differentiate along the monocytic lineage was made 30 years ago; however, it remains to translate this into a clinically meaningful strategy. This is a review of published clinical experience regarding the use of Vitamin D and its analogs, either alone or in combination with other agents, to treat AML...
2012: Leukemia Research and Treatment
journal
journal
44152
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.